For Research Use Only. Not for Human Consumption.
Recorded market$58.32Recorded exact-size market estimate: 58.32 USD for one 10 mg container (5.832452 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$76.74Member price$69.06No member savings vs. this market reference
Combined GHRH analog and secretagogue research blend.
Exact-size price research
Supplier observation dates: Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$6.91/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:31 UTC. 5 mg CJC-1295 no DAC + 5 mg Ipamorelin = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Drexa Labs Oct 11, 2026 UTC | One 10 mg container; 64.00 USD | $6.40/mg | lyophilized powder; InStock (68) Price observation; no COA authentication is implied by inclusion. |
| Go Alpha Labs Oct 11, 2026 UTC | One 10 mg container; 69.99 USD | $7.00/mg | powder/lyophilized (publisher stated); InStock Price observation; no COA authentication is implied by inclusion. |
| 24Peptides / Grail Formula Oct 11, 2026 UTC | One 10 mg container; 54.00 EUR | $6.05/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
| BioEdge Research Labs Oct 11, 2026 UTC | One 10 mg container; 59.00 USD | $5.90/mg | lyophilized powder; InStock Price observation; no COA authentication is implied by inclusion. |
| PureDose Labs Oct 11, 2026 UTC | One 10 mg container; 49.99 USD | $5.00/mg | lyophilized powder; in stock Open exact blend5mg CJCNoDAC +5mgIPA per vial; explicitlylyophilizedpowder. Qty1 current49.99USD confirmedProductOffer. WhatsIncluded LyophilizedVial, no kit/minimum. Qualification Termsapplyonlypurchasing, noentrygate afterstableload. PURE couponexcluded. Price observation; no COA authentication is implied by inclusion. |
| PatriotChems Oct 11, 2026 UTC | One 10 mg container; 44.99 USD | $4.50/mg | lyophilized powder; in stock Exactco-lyophilized5mgCJCNoDAC+5mgIPA pervial explicitlybodyFAQ. Oneunit44.99,qty1, primaryProductOfferUSD44.99. Age-only Yes/No overlay leftuntouched underexistingreadonlymethod; no professional/Terms entrycertification. Bulkexcluded. Price observation; no COA authentication is implied by inclusion. |
| Ascend Science Oct 11, 2026 UTC | One 10 mg container; 80.00 USD | $8.00/mg | lyophilized powder; in stock Explicitselected5mg CJCNoDAC+5mgIPA, total10mg lyophilizedpowder vial; qty1 one-timepurchase. Base80USD exactProductOffer;52requiresHALLOWEENcoupon soexcluded. Optionalsubscription/bulk excluded. Stablepage openly browseable, no professional/accountentrygate. Price observation; no COA authentication is implied by inclusion. |
| Peptid Haus Oct 11, 2026 UTC | One 10 mg container; 39.99 EUR | $4.48/mg | lyophilized powder; in_stock Exact5+5mg noDAC blend lyophpowder in glassvial, qty1 onevialphoto, no multipack/minimum. CurrentpublicEUR39.99sale vs50.50previous; notcoupon/subscription. Header no tax included. Age/basiclegalresearch-only notice with noTerms/professional acceptance retained readonly, noYesclicked. Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides Oct 11, 2026 UTC | One 10 mg container; 60.00 USD | $6.00/mg | lyophilized powder; in_stock Productinformation normalopen publicdialog explicitlyophpowder3mlvial10mg. Primary productcard image visiblyCONTENTS:CJC5mg Ipa5mg and vial5mg/5mg; ProductsubjectOfCOAtitlealso5mg/5mg. ProductOfferUSD60. Qty1oneproduct, multipacktiersignored. Noentrygate, 20%couponnotapplied. Price observation; no COA authentication is implied by inclusion. |
| Instant Peptides Oct 11, 2026 UTC | One 10 mg container; 49.95 USD | $5.00/mg | lyophilized powder; in stock Explicit5+5 noDAC blend10mglyophilized in3mlvial,qty1unitprice49.95USDschema. Bulk3/5/10packs andkit20promo ignored; one-vial regular quote no entry gate. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “CJC-1295 / Ipamorelin Blend | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/cjc-1295-ipamorelin-blend/ Accessed [your access date].
Source page: https://peptideserum.com/product/cjc-1295-ipamorelin-blend/
A combination vial pairing a GHRH analog with a selective secretagogue pentapeptide for combined-pathway endocrine research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
A CJC/ipamorelin blend combines substances investigated through different growth-hormone signaling pathways. A plausible combination mechanism is not a clinical trial of the blend. The first questions are which CJC-related molecule is present, what the individual amounts are, and whether the claimed outcome was actually measured for that combination.
CJC-containing blends may be labeled without a clear distinction between the long-acting DAC construct and a differently specified short-acting analogue. That ambiguity changes how component evidence can be interpreted.
Ipamorelin is a separate pentapeptide secretagogue. A paper about one component does not authenticate, characterize or validate the premixed combination.
The directly reviewed sources concern individual components. They do not establish an effective blend ratio, improved sleep, fat loss or recovery for a catalog mixture. Results cannot be added together to predict a combined clinical effect.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Component-only human study: original long-acting CJC-1295 Reading scope: PubMed abstract and bibliographic record; not full-text review |
Investigators measured sustained GH and IGF-1 responses to CJC-1295. | Ipamorelin was not the tested combination partner, and the study does not validate a no-DAC or premixed product. |
| Ipamorelin, the first selective growth hormone secretagogue.
Component-only ipamorelin pharmacology in cells, rats and swine Reading scope: PubMed abstract and bibliographic record; not full-text review |
Ipamorelin stimulated GH release with a selective hormone-response pattern under the reported experimental conditions. | Animal selectivity does not establish complete human endocrine safety or clinical benefit of a CJC/ipamorelin combination. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Biological pathways can interact in ways that cannot be predicted by simply combining single-agent findings. A direct comparison would need the precise formulations, component amounts, control groups and a relevant patient outcome.
The animal ipamorelin paper’s limited ACTH/cortisol response does not prove that a blend has no effects outside GH. The species, exposures and addition of another agent all matter.
A ratio printed on a vial describes composition if verified. It does not demonstrate that researchers selected that ratio as optimal or safe.
Component trials cannot establish the adverse-event profile of a mixture. They also do not resolve stability, aggregation or impurity questions created by a combined formulation.
A favorable short-term result for one agent is not evidence of safe long-term combined hormone stimulation.
Component-only research schedules are not a protocol for the blend. Do not combine a CJC schedule and an ipamorelin schedule into an inferred personal regimen.
When comparing experimental exposure, record the CJC construct and each component quantity separately. DAC status affects persistence and cannot be omitted from the comparison.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Require identity and content results for both components, with CJC modification status and the declared ratio clearly specified.
A single total purity number does not show that both components are present in the stated amounts. Individual-ingredient certificates also do not automatically validate a final mixed vial.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. Different mechanisms can motivate a hypothesis, but a claim of greater benefit requires a direct comparison with the individual components and an appropriate control.
No. The individual quantities and verified ratio are needed. An undifferentiated total cannot support meaningful comparison between products or studies.
This companion to the CJC / Ipamorelin blend research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Component-only research schedules are not a protocol for the blend. Do not combine a CJC schedule and an ipamorelin schedule into an inferred personal regimen.
When comparing experimental exposure, record the CJC construct and each component quantity separately. DAC status affects persistence and cannot be omitted from the comparison.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.